4.5 Review

The N-myc Oncogene: Maximizing its Targets, Regulation, and Therapeutic Potential

Journal

MOLECULAR CANCER RESEARCH
Volume 12, Issue 6, Pages 815-822

Publisher

AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1541-7786.MCR-13-0536

Keywords

-

Funding

  1. Prostate Cancer Foundation (PCF) Young Investigator
  2. Damon Runyon Cancer Research Foundation [CI-67-13]
  3. Department of Defense [PC121341]

Ask authors/readers for more resources

N-myc (MYCN), a member of the Myc family of basic-helix-loop-helix-zipper (bHLHZ) transcription factors, is a central regulator of many vital cellular processes. As such, N-myc is well recognized for its classic oncogenic activity and association with human neuroblastoma. Amplification and overexpression of N-myc has been described in other tumor types, particularly those of neural origin and neuroendocrine tumors. This review outlines N-myc's contribution to normal development and oncogenic progression. In addition, it highlights relevant transcriptional targets and mechanisms of regulation. Finally, the clinical implications of N-Myc as a biomarker and potential as a target using novel therapeutic approaches are discussed. (C) 2014 AACR.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available